NAS:RDHL (Israel) Also trade in: Germany Israel

Redhill Biopharma Ltd

$ 7.42 -0.22 (-2.88%)
Volume: 16,393 Avg Vol (1m): 48,600
Market Cap $: 211.49 Mil Enterprise Value $: 165.95 Mil
P/E (TTM): 0.00 P/B: 5.04
Earnings Power Value -1641.96
Net Current Asset Value 1.17
Tangible Book 1.28
Projected FCF -6.92
Median P/S Value 7.19
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
80.33% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
RDHL: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
N/A
Equity-to-Asset 0.72
Equity-to-Asset ranked higher than
63.70% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
RDHL: 0.72
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.68, Med: 0.85, Max: 0.95
Current: 0.72
0.68
0.95
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.52
DISTRESS
GREY
SAFE
Beneish M-Score -3.17
Not Manipulator
Manipulator

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -503.71
Operating Margin ranked lower than
73.61% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
RDHL: -503.71
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -730066.67, Med: -32386.72, Max: -153.22
Current: -503.71
-730066.67
-153.22
Net Margin % -506.40
Net Margin ranked lower than
73.23% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
RDHL: -506.4
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -703000, Med: -46953.75, Max: -152.71
Current: -506.4
-703000
-152.71
ROE % -99.32
ROE ranked lower than
75.73% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
RDHL: -99.32
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -165.04, Med: -63.35, Max: -47.84
Current: -99.32
-165.04
-47.84
ROA % -75.06
ROA ranked lower than
79.43% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
RDHL: -75.06
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -153.6, Med: -56.5, Max: -41.65
Current: -75.06
-153.6
-41.65
ROC (Joel Greenblatt) % -1776.92
ROC (Joel Greenblatt) ranked lower than
53.86% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
RDHL: -1776.92
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -26314.94, Med: -1271.66, Max: -83.98
Current: -1776.92
-26314.94
-83.98
3-Year Total Revenue Growth Rate 1307.30
3-Year Revenue Growth Rate ranked lower than
76.19% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
RDHL: 0
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -67.2, Max: 423.5
Current: 0
0
423.5
3-Year Total EBITDA Growth Rate -21.50
3-Year EBITDA Growth Rate ranked lower than
81.17% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
RDHL: 4.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -33.8, Med: -2.1, Max: 9.1
Current: 4.6
-33.8
9.1
3-Year EPS w/o NRI Growth Rate 3.60
3-Year EPS w/o NRI Growth Rate ranked lower than
80.60% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
RDHL: 3.6
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -26, Med: 2.65, Max: 25.9
Current: 3.6
-26
25.9

» RDHL's 30-Y Financials

Financials (Next Earnings Date: 2019-08-30)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:RDHL

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 0
Compare NAS:LJPC XAMS:KDS XKRX:200670 AMEX:CVM SZSE:002680 AMEX:RFL NAS:OSMT OSTO:IBT B NAS:ARDX NAS:ADMA NAS:MLND XKRX:203690 NAS:ALDX MIL:MLM ROCO:6586 XPAR:POXEL NAS:STRO NAS:ENOB AMEX:OCX ROCO:6617
Traded in other countries 2RH.Germany
Address 21 Ha’arba’a Street, Tel Aviv, ISR, 64739
Redhill Biopharma Ltd is a specialty biopharmaceutical company, primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases and cancer. The company promotes two gastrointestinal products in the U.S. - Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis, and EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Ratios

Current vs industry vs history
PB Ratio 5.04
PB Ratio ranked higher than
55.61% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
RDHL: 5.04
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.01, Med: 4.75, Max: 10.7
Current: 5.04
2.01
10.7
PS Ratio 23.75
PS Ratio ranked lower than
59.09% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
RDHL: 23.75
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 11.13, Med: 23.05, Max: 5040
Current: 23.75
11.13
5040
EV-to-EBIT -4.33
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
RDHL: -4.33
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -20.7, Med: -5.7, Max: -0.9
Current: -4.33
-20.7
-0.9
EV-to-EBITDA -4.39
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
RDHL: -4.39
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -20.8, Med: -5.8, Max: -0.9
Current: -4.39
-20.8
-0.9
EV-to-Revenue 21.71
EV-to-Revenue ranked lower than
53.96% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
RDHL: 21.71
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 6.7, Med: 20.4, Max: 3218.4
Current: 21.71
6.7
3218.4
Current Ratio 4.09
Current Ratio ranked lower than
52.61% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
RDHL: 4.09
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 3.26, Med: 8.11, Max: 36.52
Current: 4.09
3.26
36.52
Quick Ratio 3.99
Quick Ratio ranked lower than
50.47% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
RDHL: 3.99
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 3.19, Med: 8.11, Max: 36.52
Current: 3.99
3.19
36.52
Days Inventory 118.61
Days Inventory ranked higher than
76.92% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
RDHL: 118.61
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 56.05, Med: 73.77, Max: 118.61
Current: 118.61
56.05
118.61
Days Sales Outstanding 67.68
Days Sales Outstanding ranked lower than
76.35% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
RDHL: 67.68
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 41.82, Med: 139.19, Max: 26766.67
Current: 67.68
41.82
26766.67
Days Payable 693.09
Days Payable ranked higher than
86.75% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
RDHL: 693.09
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 22.94, Med: 427.66, Max: 824.94
Current: 693.09
22.94
824.94

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -22.10
3-Year Share Buyback Rate ranked lower than
59.98% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
RDHL: -22.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -88.6, Med: -29.8, Max: -18.8
Current: -22.1
-88.6
-18.8

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 5.80
Price-to-Tangible-Book ranked higher than
57.27% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
RDHL: 5.8
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.02, Med: 4.01, Max: 8.69
Current: 5.8
2.02
8.69
Price-to-Median-PS-Value 1.03
Price-to-Median-PS-Value ranked higher than
63.42% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
RDHL: 1.03
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.64, Med: 0.95, Max: 111.5
Current: 1.03
0.64
111.5
Earnings Yield (Joel Greenblatt) % -23.01
Earnings Yield (Greenblatt) ranked lower than
85.01% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
RDHL: -23.01
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -112.1, Med: -17.4, Max: -4.8
Current: -23.01
-112.1
-4.8

More Statistics

Revenue (TTM) (Mil) $ 7.65
EPS (TTM) $ -1.5
Beta 2.67
Volatility % 83.85
52-Week Range $ 5.13 - 11.49
Shares Outstanding (Mil) 28.37

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y